Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum. Speaking on Novartis ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

In 2024, Bayer chief Bill Anderson’s total compensation fell about 21% to 8.84 million euros ($9.6 million). The decline ...

Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company. The Swiss group will see major ...

New CEO Vas Narasimhan wants to cut Novartis' R&D costs by using digital tech – and with this in mind the firm has scaled up a project involving virtual clinical trials. The Swiss pharma company ...

Novartis’ new CEO Vas Narasimhan has said he wants to cut R&D costs by using digital tech, and has followed through by scaling up a virtual clinical trials collaboration with startup firm ...

While CEO-designate Vas Narasimhan kept tightlipped on this point in the press conference, an answer came a few hours later, with a deal with groundbreaking gene therapy company Spark Therapeutics ...

Novartis' chief executive, Vas Narasimhan, said that the licensing deal "bolsters our neuroscience pipeline and reflects our strategic focus and commitment to explore new and potentially ...

said chief executive Vas Narasimhan. The event comes just over a year after Novartis completed the dismantling of its diversified life sciences model with the spinout of generic and biosimilar ...